Literature DB >> 5071034

Potentiation of the toxicity of several antitumor agents by Salmonella typhosa endotoxin.

W C Rose, S G Bradley, I P Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5071034     DOI： 10.1016/0041-008x(72)90209-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN： 0041-008X            Impact factor:   4.219


× No keyword cloud information.
  9 in total

1.  Enhanced toxicity for mice of combinations of bacterial lipopolysaccharide and vincristine.

Authors:  A E Munson; D C Drummond; A C Adams; S G Bradley
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

2.  Enhanced toxicity for mice of pactamycin with bacterial endotoxin.

Authors:  S G Bradley; W C Rose
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

3.  Enhanced toxicity for mice of 6-mercaptopurine with bacterial endotoxin.

Authors:  N M Marecki; S G Bradley
Journal:  Antimicrob Agents Chemother       Date:  1974-04       Impact factor: 5.191

4.  Potentiation of the toxicity of mithramycin by bacterial lipopolysaccharide.

Authors:  S G Bradley; A C Adams; M C Smith
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

5.  Effects of endotoxin on the pharmacology of antineoplastic agents.

Authors:  K Lu; M G Rosenblum; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Endotoxin toxicity in rats with 6-sulfanilamidoindazole arthritis.

Authors:  M L Miller; C O Samuelson; J R Ward; R N Hiramoto
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

7.  Synergistic effect of pactamycin and sparsomycin on Mycoplasma-induced lethal toxicity of mice.

Authors:  M G Gabridge
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

8.  Enhanced toxicity for mice of combinations of bacterial endotoxin with antitumor drugs.

Authors:  N M Marecki; S G Bradley
Journal:  Antimicrob Agents Chemother       Date:  1973-05       Impact factor: 5.191

9.  Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission.

Authors:  Satoshi Ohno; Yoshiteru Sumiyoshi; Katsuyoshi Hashine; Akitomi Shirato; Satoru Kyo; Masaki Inoue
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-18       Impact factor: 2.629
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.